πŸ‡ΊπŸ‡Έ FDA
Patent

US 10822422

Antibodies against TL1a and uses thereof

granted A61KA61K2039/505A61P

Quick answer

US patent 10822422 (Antibodies against TL1a and uses thereof) held by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
Grant date
Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61P, A61P1/00, A61P1/04